References

tiblj

Туберкулез и болезни легких

Tuberculosis and Lung Diseases

2075-12302542-1506

Медицинские знания и технологии

10.21292/2075-1230-2020-98-5-6-14

tiblj-1420

Research Article

ОБЗОР

REVIEW

BCG-вакцинирование как протекция от COVID-19: эпидемиологические и молекулярно-биологические аспекты

BCG vaccination as protection from COVID-19: epidemiological and molecular biological aspects

Шварц

Я. Ш.

Shvartz

Ya. Sh.

yshschwartz@mail.ru

Ставицкая

Н. В.

Stavitskaya

N. V.

https://orcid.org/0000-0003-1878-4467

Кудлай

Д. А.

Kudlay

D. A.

ФГБУ «Новосибирский научно-исследовательский институт туберкулеза» МЗ РФРоссияNovosibirsk Tuberculosis Research InstituteRussian Federation

ФГБУ «ГНЦ Институт иммунологии» ФМБА РоссииРоссияNRC Institute of Immunology FMBA of RussiaRussian Federation

2020

02062020

985614

2020

Шварц Я.Ш., Ставицкая Н.В., Кудлай Д.А.

Shvartz Y.S., Stavitskaya N.V., Kudlay D.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.tibl-journal.com/jour/article/view/1420

В обзоре рассматривается недавно появившаяся гипотеза о том, что национальная политика BCG-вакцинации влияет на распространение COVID-19 в разных странах. Представлены сведения из 70 источников с эпидемиологическими показателями, свидетельствующие за и против данной гипотезы, с описанием возможных механизмов неспецифического противовирусного действия BCG-иммунизации. Сделан вывод, что для верификации или опровержения гипотезы пока недостаточно данных и в данный момент использование вакцины BCG для предотвращения распространения инфекции даже в группах высокого риска было бы необоснованно.

The article presents a review of the recent hypothesis that the national policy of BCG-vaccination affects the spread of COVID-19 in different countries. It contains the information from 70 publications with epidemiological indicators, providing pros and cons of this hypothesis, with the description of possible mechanisms of non-specific antiviral action of BCG vaccine. It is concluded that there are not enough data to verify or refute the hypothesis, and at the moment the use of BCG vaccine to prevent the spread of the infection even in high-risk groups would be unreasonable.

CG-вакцинированиеCOVID-19коронавирус SARS-CoV-2заболеваемостьсмертностьпротивовирусный иммунитет

BCG vaccinationCOVID-19coronavirus SARS-CoV-2incidencemortalityvirus-induced immunity

References1

Шварц Я. Ш., Белогородцев С. Н., Филимонов П. Н., Селедцова Г. В. Действие модуляторов активности мевалонатного биохимического пути на реактивность макрофагов при экспериментальном нефросклерозе // Мед. иммунология. – 2009. – № 11. – С. 499-508.

Shvarts Ya.Sh., Belogorodtsev S.N., Filimonov P.N., Seledtsova G.V. Effects of mevalonate pathway modulators upon reactivity of macrophages in experimental nephrosclerosis. Med. Immunologiya, 2009, no. 11, pp. 499-508. (In Russ.)

Шварц Я. Ш., Хощенко О. М., Душкин М. И., Феофанова Н. А. Действие холестерина и агонистов гормональных ядерных рецепторов на продукцию трансформирующего фактора роста-β в макрофагах // Бюл. эксперим. биологии и медицины. – 2009. – № 148. – С. 294-297.

Shvarts Ya.Sh., Khoschenko O.M., Dushkin M.I., Feofanova N.А. The effect of cholesterol and agonists of hormonal nuclear receptors on the production of the transforming growth factor-β in macrophages. Byul. Eksperim. Biologii I Meditsiny, 2009, no. 148, pp. 294-297. (In Russ.)

Aaby P., Kollmann T., Benn C. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges // Nat. Immunol. – 2014. – № 15. – Р. 895-899. https://doi.org/10.1038/ni.2961.

Aaby P., Kollmann T., Benn C. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat. Immunol., 2014, no. 15, pp. 895-899. https://doi.org/10.1038/ni.2961.

Abubakar I., Pimpin L., Ariti C., Beynon R., Mangtani P. et al. Systematic review and meta-analysis of the current evidence on the duration of protection by Bacillus Calmette-Guérin vaccination against tuberculosis // Health Technol. Assess. – 2013. – № 37. – P. 1-372. doi: 10.3310/hta17370.

Abubakar I., Pimpin L., Ariti C., Beynon R., Mangtani P. et al. Systematic review and meta-analysis of the current evidence on the duration of protection by Bacillus Calmette-Guérin vaccination against tuberculosis. Health Technol. Assess., 2013, no. 37, pp. 1-372. doi: 10.3310/hta17370.

Allen I. C., Scull M. A., Moore C. B., Holl E. K., McElvania-TeKippe E. et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA // Immunity. – 2009. – Vol. 30, № 4. – P. 556-565.

Allen I.C., Scull M.A., Moore C.B., Holl E.K., McElvania-TeKippe E. et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity, 2009, vol. 30, no. 4, pp. 556-565.

Aronson N. E., Santosham M., Comstock G. W., Howard R. S., Moulton L. H. et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study // JAMA. – 2004. – Vol. 291, № 17. – P. 2086-2091.

Aronson N.E., Santosham M., Comstock G.W., Howard R.S., Moulton L.H. et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA, 2004, vol. 291, no. 17, pp. 2086-2091.

Arts R. J. W., Moorlag S. J. C. F. M., Novakovic B., Li Y., Wang S. Y. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity // Cell Host & Microbe. – 2018. – Vol. 23, № 1. – P. 89-100. doi: 10.1016/j.chom.2017.12.010.

Arts R.J.W., Moorlag S.J.C.F.M., Novakovic B., Li Y., Wang S.Y. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host & Microbe, 2018, vol. 23, no. 1, pp. 89-100. doi: 10.1016/j.chom.2017.12.010.

Asahara M. The effect of BCG vaccination on COVID-19 examined by a statistical approach: no positive results from the Diamond Princess and cross-national differences previously reported by world-wide comparisons are flawed in several ways. doi: https://doi.org/10.1101/2020.04.17.20068601.

BCG vaccination and COVID-19. Scientific brief. WHO, April 12, 2020.

Barreto M. L., Cunha S. S., Pereira S. M., Genser B., Hijjar M. A. et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil // Int. J. Tuberc. Lung Dis. – 2005. – Vol. 9, № 10. – P. 1171-1173.

Barreto M.L., Cunha S.S., Pereira S.M., Genser B., Hijjar M.A. et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int. J. Tuberc. Lung Dis., 2005, vol. 9, no. 10, pp. 1171-1173.

Bekkering S., Arts R. J. W., Novakovic B., Kourtzelis I., van der Heijden C. et al. Metabolic induction of trained immunity through the mevalonate pathway // Cell. – 2018. – Vol. 172, № 1-2. – P. 135-146. https://doi.org/10.1016/j.cell.2017.11.025 PMID: 29328908.

Bekkering S., Arts R.J.W., Novakovic B., Kourtzelis I., van der Heijden C. et al. Metabolic induction of trained immunity through the mevalonate pathway. Cell, 2018, vol. 172, no. 1-2, pp. 135-146. https://doi.org/10.1016/j.cell.2017.11.025 PMID: 29328908.

Berg M. K., Yu Q., Salvador C. E., Melani I., Kitayama S. Mandated BCG vaccination predicts flattened curves for the spread of COVID-19. doi: 10.1101/2020.04.05.20054163.

Berg M.K., Yu Q., Salvador C.E., Melani I., Kitayama S. Mandated BCG vaccination predicts flattened curves for the spread of COVID-19. doi: 10.1101/2020.04.05.20054163.

Biering-Sørensen S., Aaby P., Lund N., Monteiro I., Jensen K. J. et al. Early BCG-Denmark and neonatal mortality among infants weighing < 2500 g: a randomized controlled trial // Clin. Infect. Dis. – 2017. ‒ Vol. 65, № 7. – P. 1183-1190.

Biering-Sørensen S., Aaby P., Lund N., Monteiro I., Jensen K.J. et al. Early BCG-Denmark and neonatal mortality among infants weighing < 2500 g: a randomized controlled trial. Clin. Infect. Dis., 2017, vol. 65, no. 7, pp. 1183-1190.

Braun J., Loyal L., Frentsch M., Wendisch D., Georg P. et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. doi: 10.1101/2020.04.17.20061440.

Brosch R., Gordon S., Garnier T., Eiglmeier K., Frigui W. et al. Genome plasticity of BCG and impact on vaccine efficacy // Proc. Natl. Acad. Sci. USA. – 2007. – Vol. 104, № 13. – P. 5596-5601.

Brosch R., Gordon S., Garnier T., Eiglmeier K., Frigui W. et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl. Acad. Sci. USA, 2007, vol. 104, no. 13, pp. 5596-5601.

Chen J. M., Islam S. T., Ren H., Liu J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety // Vaccine. – 2007. Vol. 25, № 48. – P. 8114-8122.

Chen J.M., Islam S.T., Ren H., Liu J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine, 2007, vol. 25, no. 48, pp. 8114-8122.

Davids V., Hanekom W. A., Mansoor N., Gamieldien H., Sebastian J. G. et al. The effect of Bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants // J. Infect. Dis. – 2006. – Vol. 193, № 4. – P. 531-536.

Davids V., Hanekom W.A., Mansoor N., Gamieldien H., Sebastian J.G. et al. The effect of Bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants. J. Infect. Dis., 2006, vol. 193, no. 4, pp. 531-536.

Dockrell H. M., Smith S. G. What have we learnt about BCG vaccination in the last 20 years? // Front. Immunol. – 24 May 2018. doi: 10.3389/fimmu.2017.01134.

Dockrell H.M., Smith S.G. What have we learnt about BCG vaccina-

Egen J. G. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas // Immunity. – 2008. – Vol. 28, № 2. – P. 271-284.

tion in the last 20 years? Front. Immunol., 24 May 2018. doi: 10.3389/

Floc'h F., Werner G. H. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guerin) // Ann. Immunol. ‒ 1976. – Vol. 127, № 2. – P. 173-186.

fimmu.2017.01134.

Fukui M., Kawaguchi K., Matsuura H. Does TB vaccination reduce COVID-19 infection? No evidence from a regression discontinuity analysis. doi: 10.1101/2020.04.13.20064287.

Egen J.G. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity, 2008, vol. 28, no. 2, pp. 271-284.

Garly M. L. et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa: A non-specific beneficial effect of BCG? // Vaccine. – 2003. – Vol. 21, № 21-22. – P. 2782-2790.

Floc'h F., Werner G.H. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guerin). Ann. Immunol., 1976, vol. 127, no. 2, pp. 173-186.

Gursel M., Gursel I. Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic? // Med. Hypotheses. – 2020., doi: 10.1016/j.mehy.2020.109707.

Fukui M., Kawaguchi K., Matsuura H. Does TB vaccination reduce COVID-19 infection? No evidence from a regression discontinuity analysis. doi: 10.1101/2020.04.13.20064287.

Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J. et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. doi: 10.1101/2020.04.19.20068015.

Garly M.L. et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa: A non-specific beneficial effect of BCG? Vaccine, 2003, vol. 21, no. 21-22, pp. 2782-2790.

Hegarty P. K., Kamat A., Zafirakis H., DiNardo A. BCG vaccination may be protective against Covid-19. https://www.researchgate.net/publication/340224580.

Gursel M., Gursel I. Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic? Med. Hypotheses, 2020., doi: 10.1016/j.mehy.2020.109707.

Hensel J., McGrail D. J., McAndrews K. M., Dowlatshahi D., LeBleu V. S. Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing. doi: 10.1101/2020.04.08.20056051.

Higgins J., Soares-Weiser K., Reingold K. Systematic review of the nonspecific effects of BCG, DTP and measles containing vaccines https://www.who.int/immunization/sage/meetings/2014/april/3_NSE_Epidemiology_review_Report_to_SAGE_14_Mar_FINAL.pdf?ua=1. 28.Hippmann G., Wekkeli M., Rosenkranz A. R., Jarisch R., Gotz M. Nonspecific immune stimulation with BCG in Herpes simplex recidivans. Follow-up 5 to 10 years after BCG vaccination // Wien Klin Wochenschr. – 1992. – Vol. 104, № 7. – P. 200-204.

Hegarty P.K., Kamat A., Zafirakis H., DiNardo A. BCG vaccination may be protective against Covid-19. https://www.researchgate.net/publication/340224580.

Hollm-Delgado M. G., Stuart E. A., Black R. E. Acute lower respiratory infection among Bacille Calmette-Guerin (BCG)-vaccinated children // Pediatrics. – 2014. – Vol. 133, № 1. – P. 73-81. doi: 10.1542/peds.2013-2218. PubMed PMID: 24379224.

Hensel J., McGrail D.J., McAndrews K.M., Dowlatshahi D., LeBleu V.S. Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing. doi: 10.1101/2020.04.08.20056051.

Hsu L. C., Ali S. R., McGillivray S., Tseng P. H., Mariathasan S. et al. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1β secretion in response to Bacillus anthracis infection and muramyl dipeptide // PNAS. – 2008. – Vol. 105. – P. 7803-7808.

https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.

Hippmann G., Wekkeli M., Rosenkranz A.R., Jarisch R., Gotz M. Nonspecific immune stimulation with BCG in Herpes simplex recidivans. Follow-up 5 to 10 years after BCG vaccination. Wien Klin Wochenschr., 1992, vol. 104, no. 7, pp. 200-204.

Jenneke L. et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study // J. Infect. Dis. – 2012. ‒ № 12. – P. 1930-1938.

Hollm-Delgado M.G., Stuart E.A., Black R.E. Acute lower respiratory infection among Bacille Calmette-Guerin (BCG)-vaccinated children. Pediatrics, 2014, vol. 133, no. 1, pp. 73-81. doi: 10.1542/peds.2013-2218. PubMed PMID: 24379224.

Kapetanovic R., Nahori M. A., Balloy V., Fitting C., Philpott D. J. et al. Contribution of phagocytosis and intracellular sensing for cytokine production by Staphylococcus aureus-activated macrophages // Infect. Immun. – 2007. – № 75. – P. 830-837.

Hsu L.C., Ali S.R., McGillivray S., Tseng P.H., Mariathasan S. et al. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1β secretion in response to Bacillus anthracis infection and muramyl dipeptide. PNAS, 2008, vol. 105, pp. 7803-7808.

Kaufmann E., Sanz J., Dunn J. L., Khan N., Mendonca L. E. et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis // Cell. – 2018. – Vol. 172, № 1-2. – P. 176-190. https://doi.org/10.1016/j.cell.2017.12.031.

https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.

Kaveh D., Garcia-Pelayo M., Hogarth P. Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis // Vaccine. – 2014. – Vol. 32, № 51. – P. 6911-6918.

Jenneke L. et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J. Infect. Dis., 2012, no. 12, pp. 1930-1938.

Kirov S. A. Association between BCG policy and COVID19 infection rates is significantly confounded by age and is unlikely to alter infection or mortality rates. April 2020. doi: 10.1101/2020.04.06.20055616.

Kapetanovic R., Nahori M.A., Balloy V., Fitting C., Philpott D.J. et al. Contribution of phagocytosis and intracellular sensing for cytokine production by Staphylococcus aureus-activated macrophages. Infect. Immun., 2007, no. 75, pp. 830-837.

Korf J., Stoltz A., Verschoor J., De Baetselier P., Grooten J. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses // Eur. J. Immunol. – 2005. – Vol. 35, № 3. – P. 890-900.

Kaufmann E., Sanz J., Dunn J.L., Khan N., Mendonca L.E. et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell, 2018, vol. 172, no. 1-2, pp. 176-190. https://doi.org/10.1016/j.cell.2017.12.031.

Kutsukake H., Nagao S., Tanaka A. Arrest of DNA replication of macrophages in BCG granuloma and peritoneal exudates by bacteria // Microbiol. Immunol. – 1990. – Vol. 34, № 2. – P. 197-210.

Kaveh D., Garcia-Pelayo M., Hogarth P. Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis. Vaccine, 2014, vol. 32, no. 51, pp. 6911-6918.

Mangtani P., Nguipdop-Djomo P., Keogh R. H., Trinder L., Smith P. G. et al. Observational study to estimate the changes in the effectiveness of Bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK // Health Technol. Assess. – 2017. – Vol. 21. – P. 1-54 doi: 10.3310/hta21390.

Kirov S.A. Association between BCG policy and COVID19 infection rates is significantly confounded by age and is unlikely to alter infection or mortality rates. April 2020. doi: 10.1101/2020.04.06.20055616.

Mathurin K. S., Martens G. W., Kornfeld H., Welsh R. M. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses // J. Virology. – 2009. – Vol. 83, № 8. – P. 3528-3539.

Korf J., Stoltz A., Verschoor J., De Baetselier P., Grooten J. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur. J. Immunol., 2005, vol. 35, no. 3, pp. 890-900.

Mendum T. A., Chandran A., Williams K. et al. Transposon libraries identify novel Mycobacterium bovis BCG genes involved in the dynamic interactions required for BCG to persist during in vivo passage in cattle // BMC Genomics. – 2019. – Vol. 20. – P. 431. doi: 10.1186/s12864-019-5791-1.

Kutsukake H., Nagao S., Tanaka A. Arrest of DNA replication of macrophages in BCG granuloma and peritoneal exudates by bacteria. Microbiol. Immunol., 1990, vol. 34, no. 2, pp. 197-210.

Miller A., Reandelar M. J., Fasciglione K., Roumenova V., Li Y. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study doi: 10.1101/2020.03.24.20042937.

Mangtani P., Nguipdop-Djomo P., Keogh R.H., Trinder L., Smith P.G. et al. Observational study to estimate the changes in the effectiveness of Bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technol. Assess., 2017, vol. 21, pp. 1-54 doi: 10.3310/hta21390.

Minnikin D. E., Parlett J. H., Magnusson M., Ridell M., Lind A. Mycolic acid patterns of representatives of Mycobacterium bovis BCG // J. General Microbiology. – 1984. – № 130. – P. 2733-2736.

Mathurin K.S., Martens G.W., Kornfeld H., Welsh R.M. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J. Virolology, 2009, vol. 83, no. 8, pp. 3528-3539.

Mitroulis I., Ruppova K., Wang B., Chen L. S., Grzybek M. et al. Modulation of myelopoiesis progenitors is an integral component of trained immunity // Cell. – 2018. – Vol. 172, № 1-2. – P. 147-161. doi: 10.1016/j.cell.2017.11.034.

Mendum T.A., Chandran A., Williams K. et al. Transposon libraries identify novel Mycobacterium bovis BCG genes involved in the dynamic interactions required for BCG to persist during in vivo passage in cattle. BMC Genomics, 2019, vol. 20, pp. 431. doi: 10.1186/s12864-019-5791-1.

Moorlag S. J. C. F. M., Arts R. J. W., van Crevel R., Netea M. G. Non-specific effects of BCG vaccine on viral infections // Clin. Microbiol. Infect. – 2019. – Vol. 25, № 12. – P. 1473-1478. doi: 10.1016/j.cmi.2019.04.020. Epub 2019 May 2.

Miller A., Reandelar M.J., Fasciglione K., Roumenova V., Li Y. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study doi: 10.1101/2020.03.24.20042937.

Nankabirwa V. et al. Child survival and BCG vaccination: a community based prospective cohort study in Uganda // BMC Public Health. – 2015. – Vol. 15, № 175. – P. 1-10.

Minnikin D.E., Parlett J.H., Magnusson M., Ridell M., Lind A. Mycolic acid patterns of representatives of Mycobacterium bovis BCG. J. General Microbiology, 1984, no. 130, pp. 2733-2736.

Netea M. G., Domínguez-Andrés J., Barreiro L. B., Chavakis T., Divangahi M. Defining trained immunity and its role in health and disease // Nat. Rev. Immunol. – 2020. – Mar 4. doi: 10.1038/s41577-020-0285-6.

Mitroulis I., Ruppova K., Wang B., Chen L. S., Grzybek M. et al. Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell, 2018, vol. 172, no. 1-2, pp. 147-161. doi: 10.1016/j.cell.2017.11.034.

Netea M. G., Quintin J., van der Meer J. W. Trained immunity: a memory for innate host defense // Cell Host Microbe. – 2011. – Vol. 9, № 5. – P. 355-361. doi: 10.1016/j.chom.2011.04.006.

Moorlag S.J.C.F.M., Arts R.J.W., van Crevel R., Netea M.G. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect., 2019, vol. 25, no. 12, pp. 1473-1478. doi: 10.1016/j.cmi.2019.04.020. Epub 2019 May 2.

Netea M. G., Joosten L. A., Latz E., Mills K. H., Natoli G. et al. Trained immunity: A program of innate immune memory in health and disease // Science. – 2016. – Vol. 352 (6284). doi: 10.1126/science.aaf1098.

Nankabirwa V. et al. Child survival and BCG vaccination: a community based prospective cohort study in Uganda. BMC Public Health, 2015, vol. 15, no. 175, pp. 1-10.

Nguipdop-Djomo P., Heldal E., Rodrigues L. C., Abubakar I., Mangtani P. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study // Lancet Infect. Dis. – 2016. – № 16. ‒ P. 219-226. doi:10.1016/S1473-3099(15)00400-4.

Netea M.G., Domínguez-Andrés J., Barreiro L.B., Chavakis T., Divangahi M. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol., 2020, Mar 4. doi: 10.1038/s41577-020-0285-6.

Ota M. O. C., Vekemans J., Schlegel-Haueter S. E. et al. Influence of Mycobacterium bovis Bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination // J. Immunology. – 2002. – Vol. 168, № 2. – P. 919-925.

Netea M.G., Quintin J., van der Meer J.W. Trained immunity: a memory for innate host defense. Cell Host Microbe, 2011, vol. 9, no. 5, pp. 355-361. doi: 10.1016/j.chom.2011.04.006.

Pitzer V. E., Chitwood M., Havumaki J., Menzies N. A., Perniciaro S. et al. The impact of changes in diagnostic testing practices on estimates of COVID-19 transmission in the United States. doi: 10.1101/2020.04.20.20073338v1.

Netea M.G., Joosten L.A., Latz E., Mills K.H., Natoli G. et al. Trained immunity: A program of innate immune memory in health and disease. Science, 2016, vol. 352 (6284). doi: 10.1126/science.aaf1098.

Rathinam V. A. K., Fitzgerald K. A. Inflammasomes and anti-viral immunity // J. Clin Immunology. – 2010. – Vol. 30, № 5. – P. 632-637.

Nguipdop-Djomo P., Heldal E., Rodrigues L.C., Abubakar I., Mangtani P. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect. Dis., 2016, no. 16, pp. 219-226. doi:10.1016/S1473-3099(15)00400-4.

Sala G., Miyakawa T. Association of BCG vaccination policy with prevalence and mortality of COVID-19. doi: 10.1101/2020.03.30.20048165.

Ota M.O.C., Vekemans J., Schlegel-Haueter S.E. et al. Influence of Mycobacterium bovis Bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J. Immunology, 2002, vol. 168, no. 2, pp. 919-925.

Schwartz Y. Sh., Svistelnik A. V. Functional phenotypes of macrophages and the M1-M2 polarization concept. Part I. Proinflammatory phenotype // Biochemistry (Moscow). – 2012. – Vol. 77, № 3. – P. 246-260.

Pitzer V.E., Chitwood M., Havumaki J., Menzies N.A., Perniciaro S. et al. The impact of changes in diagnostic testing practices on estimates of COVID-19 transmission in the United States. doi: 10.1101/2020.04.20.20073338v1.

Seishima M., Fujisawa T., Yamanaka S., Ishii N., Mori S. et al. BCG granuloma appearing more than 50 years after vaccination // Arch. Dermatol. – 2006. – Vol. 142. – P. 249-250. Doi: 10.1001/archderm.142.2.249.

Rathinam V.A.K., Fitzgerald K.A. Inflammasomes and anti-viral immunity. J. Clin. Immunology, 2010, vol. 30, no. 5, pp. 632-637.

Sergerie Y., Boivin G., Rivest S. Tumor necrosis factor-a and interleukin-1b play a critical role in the resistance against lethal herpes simplex virus encephalitis // J. Infect. Dis. – 2007. – Vol. 196, № 6. – P. 853-860.

Sala G., Miyakawa T. Association of BCG vaccination policy with prevalence and mortality of COVID-19. doi: 10.1101/2020.03.30.20048165.

Shann F. Nonspecific effects of vaccines and the reduction of mortality in children // Clin. Ther. – 2013. ‒ Vol. 35, № 2. – P. 109-114.

Schwartz Y.Sh., Svistelnik A.V. Functional phenotypes of macrophages and the M1-M2 polarization concept. Part I. Proinflammatory phenotype. Biochemistry (Moscow), 2012, vol. 77, no. 3, pp. 246-260.

Shet A., Ray D., Malavige N., Santosham M., Bar-Zeev N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. doi: 10.1101/2020.04.01.20049478.

Seishima M., Fujisawa T., Yamanaka S., Ishii N., Mori S. et al. BCG granuloma appearing more than 50 years after vaccination. Arch. Dermatol., 2006, vol. 142, pp. 249-250. doi: 10.1001/archderm.142.2.249.

Shivendu S., Chakraborty S., Onuchowska A., Patidar A., Srivastava A. Is there evidence that BCG vaccination has non-specific protective effects for COVID 19 infections or is it an illusion created by lack of testing? doi: 10.1101/2020.04.18.20071142.

Sergerie Y., Boivin G., Rivest S. Tumor necrosis factor-a and interleukin-1b play a critical role in the resistance against lethal herpes simplex virus encephalitis. J. Infect. Dis., 2007, vol. 196, no. 6, pp. 853-860.

Spencer J. C., Ganguly R., Waldman R. H. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin // J. Infect. Dis. – 1977. – Vol. 136, № 2. – P. 171-175. doi: 10.1093/infdis/136.2.171.

Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. Clin. Ther., 2013, vol. 35, no. 2, pp. 109-114.

Sterne J. A., Rodrigues L. C., Guedes I. N. Does the efficacy of BCG decline with time since vaccination? // Int. J. Tuberc. Lung. Dis. – 1998. – Vol. 2, № 3. – P. 200-207.

Shet A., Ray D., Malavige N., Santosham M., Bar-Zeev N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. doi: 10.1101/2020.04.01.20049478.

Szigeti R., Kellermayer D., Kellermayer R. BCG protects against COVID-19? A word of caution. doi: 10.1101/2020.04.09.20056903.

Thomas P. G. et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza a virus via the regulation of caspase-1 // Immunity. – 2009. – Vol. 30, № 4. – P. 566-575.

Spencer J.C., Ganguly R., Waldman R.H. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin. J. Infect. Dis., 1977, vol. 136, no. 2, pp. 171-175. doi: 10.1093/infdis/136.2.171.

Uthayakumar D., Paris S., Chapat L., Freyburger L., Poulet H. et al. Non-specific effects of vaccines illustrated through the BCG example: from observations to demonstrations // Front Immunol. – 2018. – № 9:2869. Published online 2018 Dec 4. doi: 10.3389/fimmu.2018.02869.

Sterne J.A., Rodrigues L.C., Guedes I.N. Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung. Dis., 1998, vol. 2, no. 3, pp. 200-207.

Vander Beken S., Al Dulayymi J., Naessens T., Koza G., Maza-Iglesias M. et al. Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern // Eur. J. Immunol. – 2011. – Vol. 41, № 2. – P. 450-460.

Szigeti R., Kellermayer D., Kellermayer R. BCG protects against COVID-19? A word of caution. doi: 10.1101/2020.04.09.20056903.

Wager L. C. M., Hole C. R., Campuzano A., Castro-Lopez N., Cai H. et al. IFN-γ immune priming of macrophages in vivo induces prolonged STAT1 binding and protection against Cryptococcus neoformans // PLoS Pathog. – 2018. – Vol. 14, № 10. ‒ Р. e1007358. https://doi.org/10.1371/journal.ppat.1007358.

Thomas P.G. et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza a virus via the regulation of caspase-1. Immunity, 2009, vol. 30, no. 4, pp. 566-575.

Wardhana, Datau E. A., Sultana A., Mandang V. V., Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly // Acta Med. Indones. – 2011. – Vol. 43, № 3. – P. 185-190.

Uthayakumar D., Paris S., Chapat L., Freyburger L., Poulet H. et al. Non-specific effects of vaccines illustrated through the BCG example: from observations to demonstrations. Front Immunol., 2018, no. 9:2869. Published online 2018 Dec 4. doi: 10.3389/fimmu.2018.02869.

Wilk A. J., Rustagi A., Zhao N. Q., Roque J., Martinez-Colon G. J. et al. A single-cell atlas of the peripheral immune response to severe COVID-19. doi: 10.1101/2020.04.17.20069930.

Vander Beken S., Al Dulayymi J., Naessens T., Koza G., Maza-Iglesias M. et al. Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern. Eur. J. Immunol., 2011, vol. 41, no. 2, pp. 450-460.

www.worldometers.info/coronavirus/

Wager L.C.M., Hole C.R., Campuzano A., Castro-Lopez N., Cai H. et al. IFN-γ immune priming of macrophages in vivo induces prolonged STAT1 binding and protection against Cryptococcus neoformans. PLoS Pathog., 2018, vol. 14, no. 10, pp. e1007358. https://doi.org/10.1371/journal.ppat.1007358.

Wardhana, Datau E.A., Sultana A., Mandang V.V., Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med. Indones., 2011, vol. 43, no. 3, pp. 185-190.

Wilk A.J., Rustagi A., Zhao N.Q., Roque J., Martinez-Colon G.J. et al. A single-cell atlas of the peripheral immune response to severe COVID-19. doi: 10.1101/2020.04.17.20069930.

www.worldometers.info/coronavirus/

The authors declare that there are no conflicts of interest present.